Samoxen said a Phase II trial of its nalmefene hydrochloride oral smoking-cessation drug showed it led to higher abstinence rates in volunteers who received 40mg doses. But the firm also reported a less-successful rate among those receiving it in 80mg doses and said the trial was designed to be "exploratory in nature."

Related Summaries